InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod

STOCKHOLM, March 15, 2023 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) today announced positive results from a pharmacokinetic (PK) study with cobitolimod in patients with moderate to severe ulcerative colitis. The systemic uptake was limited both for patients with active…

Leave a Reply

Your email address will not be published. Required fields are marked *